#Sweden #Stockholm #Sobi #Altuvoct #WFH 2025

Sobi Unveils Groundbreaking Clinical Insights at WFH 2025 Summit on Hemophilia Management

Sobi®, a leading international biopharmaceutical company, recently showcased significant clinical data about its innovative haemophilia treatment during the WFH 2025 Comprehensive Care Summit held in Dubai from April 23 to 25. The event is a pivotal gathering for healthcare professionals, researchers, and patients dedicated to advancing treatment for haemophilia.

During the summit, Sobi presented findings from the XTEND phase 3 clinical program, which evaluated the effectiveness of Altuvoct® (efanesoctocog alfa). This therapy represents a revolutionary approach for treating haemophilia A, aiming to enhance patients' quality of life through improved joint health and surgical outcomes. As highlighted by Dr. Lydia Abad-Franch, Sobi's Chief Medical Officer, sharing these outcomes with the global haemophilia community is crucial for fostering awareness and understanding of progressive treatment paradigms that maintain factor VIII levels in the non-haemophilia range.

Key Presentations and Studies

At the WFH 2025 summit, several key presentations were scheduled, including:

• - Oral Presentation on Joint Health and Quality of Life: A plain language summary discussing the correlation between joint health and patient-reported quality of life outcomes derived from data on efanesoctocog alfa in adults and adolescents with severe haemophilia A. This presentation took place on April 24, sparking discussions on holistic care management approaches.
• - Perioperative Management in Dental Surgery: An oral presentation on experiences covering four years of efanesoctocog alfa use during dental procedures, emphasizing its relevance in perioperative management for patients with severe haemophilia A.
• - Poster Presentations: Several studies highlighted the effectiveness of efanesoctocog alfa through poster presentations. Topics ranged from the long-term outcomes of prophylaxis in adolescents and adults to the initial two-year results of weekly treatments in children, showcasing the therapy’s sustained benefits and safety profile.

Innovative Therapy Profile

Efanesoctocog alfa stands out as a novel therapy in the weekly factor VIII treatment landscape, designed to maintain near-normal factor activity through innovative Fc fusion technology. This advancement enables extended circulation time in the body, significantly improving bleed protection for individuals with haemophilia A while utilizing a convenient once-weekly dosing regimen.

Sobi’s commitment to improving the lives of those affected by rare diseases is evident through the collaboration with Sanofi in the development and commercialization of their therapies. These partnerships empower Sobi to expand the availability of innovative treatment solutions across diverse regions, with robust research efforts aimed at enhancing care for patients with haemophilia and other complex conditions.

The Path Forward

The insights shared by Sobi at the WFH 2025 Comprehensive Care Summit underscore the importance of continuous dialogue and sharing of clinical data within the haemophilia community. With growing awareness and adoption of innovative therapies like Altuvoct®, the future looks promising for individuals living with haemophilia. Sobi remains dedicated to transforming lives through ongoing research, investment in new treatment developments, and commitment to equitable access across markets worldwide.

As Sobi looks forward toward further advancements and collaborations in the field of hemophilia treatment, it is clear that the company is not just refining existing therapies but is also pioneering new avenues for care that can lead to markedly improved patient outcomes. The dialogue fostered at events like the WFH Summit is vital in shaping the future of haemophilia care, and Sobi stands at the forefront of this important global initiative.